¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"integration host factor"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
3
¿µ¹®
ÇѱÛ
antiphagocytic factor
Çׯ÷½ÄÀÎÀÚ, Ç׎½ÄÀÎÀÚ
antiplatelet factor
Ç×Ç÷¼ÒÆÇÀÎÀÚ
antirachitic factor
Ç×±¸·çº´ÀÎÀÚ
antiscorbutic factor
Ç×±«Ç÷º´ÀÎÀÚ
antisterility factor
Ç׺ÒÀÓÀÎÀÚ
atrial natriuretic factor
½É¹æ³ªÆ®·ýÀÌ´¢ÀÎÀÚ, ½É¹æ¼ÒµãÀÌ´¢ÀÎÀÚ
activation factor
Ȱ¼ºÀÎÀÚ
absorbed dose conversion factor
Èí¼ö¼±·®º¯È¯°è¼ö
alveolar dilution factor
ÆóÆ÷Èñ¼®ÀÎÀÚ, ÇãÆÄ²Ê¸®Èñ¼®ÀÎÀÚ
amplification factor
ÁõÆøÀÎÀÚ
behavioral risk factor
ÇൿÀ§Çè¿äÀÎ
coagulation factor
ÀÀ°íÀÎÀÚ
coagulation factor inhibitor
ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
colony-stimulating factor
Áý¶ôÀÚ±ØÀÎÀÚ
common factor
°øÅëÀÎÀÚ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
3
¿µ¹®
ÇѱÛ
host-range mutant
¼÷ÁÖ¹üÀ§º¯ÀÌÁÖ, ¼÷ÁÖ¿ªµ¹¿¬º¯ÀÌü
intermediate host
Áß°£¼÷ÁÖ
natural host
ÀÚ¿¬¼÷ÁÖ
paratenic host
¿¬Àå¼÷ÁÖ
primary host
(¢¡definitive host) ÃÖÁ¾¼÷ÁÖ
reservoir host
º¸À¯¼÷ÁÖ
susceptible host
°¨¼ö¼º¼÷ÁÖ
transport host
¿î¹Ý¼÷ÁÖ
unnatural host
ºñÈ£Àû¼÷ÁÖ
vector host
¸Å°³¼÷ÁÖ
vicarious host
´ë¸®¼÷ÁÖ
absorbed dose conversion factor
Èí¼ö¼±·®º¯È¯°è¼ö
activation factor
Ȱ¼ºÀÎÀÚ
alveolar dilution factor
ÆóÆ÷Èñ¼®ÀÎÀÚ, ÇãÆÄ²Ê¸®Èñ¼®ÀÎÀÚ
amplification factor
ÁõÆøÀÎÀÚ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
3
¿µ¹®
ÇѱÛ
Factor IX
IX ÀÀ°íÀÎÀÚ(ëêͳì×í)
Factor V
V ÀÀ°íÀÎÀÚ(ëêͳì×í)
Factor VII
VII ÀÀ°íÀÎÀÚ(ëêͳì×í)
Factor VIII
VIII ÀÀ°íÀÎÀÚ(ëêͳì×í)
Factor X activated
Ȱ¼ºÈ(üÀàõûù)µÈ X ÀÀ°íÀÎÀÚ(ëêͳì×í)
Factor XI
XI ÀÀ°íÀÎÀÚ(ëêͳì×í)
Factor XII
XII ÀÀ°íÀÎÀÚ(ëêͳì×í)
Fibrin-stabilizing factor
¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ(¡äÌïÒì×í)
Fibroblast growth factor
¼¶À¯¸ð¼¼Æ÷(àéë«Ù½á¬øà)¼ºÀå¿äÀÎ(à÷íþé©ì×)
G-CSF (Granulocyte colony-stimulating factor)
°ú¸³¼¼Æ÷±ºÃËÁøÀÎÀÚ(Î¨Ø£á¬øàÏØõµòäì×í)
GH releasing factor
¼ºÀå(à÷íþ)È£¸£¸ó À¯¸®ÀÎÀÚ(ë´×îì×í).
GH releasing factor
¼ºÀåÈ£¸£¸óÀ¯¸®ÀÎÀÚ.
Growth factor
¼ºÀåÀÎÀÚ(à÷íþì×í)
Hageman factor
ÇϰԸ¸ÀÎÀÚ
Hydrostatic factor
Á¤¼öÀÎÀÚ(ð¡â©ì×í)
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
3
¿µ¹®
ÇѱÛ
host-controlled modification
¼÷ÁÖÁ¶Àý¼ö½Ä
host-parasite relationship
¼÷ÁÖ-±â»ýü »óÈ£°ü°è
host-parasite relationship
¼÷ÁÖ±â»ýü°ü°è
host-parasite relationships
¼÷ÁÖ ±â»ýÃæ(»ó°ü) °ü°è
host-range mutant
¼÷ÁÖ¹üÀ§º¯ÀÌÁÖ
intermediate host
Áß°£¼÷ÁÖ
mutant, host range
¼÷ÁÖ¿ª µ¹¿¬º¯ÀÌÁÖ
pneumonia,in immunocompromised host
¸é¿ª±â´ÉÀúÇϼ÷ÁÖÀÇ (Øóæ¹Ñ¦Òöî¸ù»âÖñ«¡)
relation[ship], host-parasite
¼÷ÁÖ-±â»ýü »óÈ£°ü°è
tumor host interaction
Á¾¾ç¼÷ÁÖ»óÈ£ÀÛ¿ë
col factor(»ýÈ) cÀÌ ÀÎÀÚ colicin factor
Äݸ®½ÅÀÎÀÚ.
lupus erythematosus factor = LE factor
È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡ì×í)
time, dose and fractionation factor, TDF factor
½Ã°£¼±·®ºÐÇÒÀÎÀÚ
absorbed dose conversion factor
Èí¼ö¼±·®º¯È¯°è¼ö
age factor
¿¬·ÉÀÎÀÚ.
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
3
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
3
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
3
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
3
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
3
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
3
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½